Literature DB >> 10842159

Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate.

M R Kibbe1, J Li, S Nie, S C Watkins, A Lizonova, I Kovesdi, R L Simmons, T R Billiar, E Tzeng.   

Abstract

OBJECTIVE: Overexpression of the inducible nitric oxide synthase (iNOS) gene inhibits neointimal hyperplasia after arterial injury. The purpose of this study was to examine the mechanism by which nitric oxide (NO) inhibits vascular smooth muscle cell (VSMC) proliferation, specifically focusing on signaling pathways known to be activated by NO, including cyclic guanosine monophosphate (cGMP), p53, and p42/44 mitogen-activated protein kinase (MAPK). METHODS AND
RESULTS: VSMCs that were subjected to iNOS gene transfer demonstrated a reduction in proliferation (80%) that was associated with a marked increase in p21 expression. The antiproliferative and p21 stimulatory effects of NO were not suppressed by the soluble guanylate cyclase inhibitor ODQ, implicating cGMP-independent signaling. The role of p53 in NO-mediated upregulation of p21 and inhibition of proliferation was evaluated using p53 -/- VSMCs. A similar reduction in cellular proliferation and upregulation of p21 expression were achieved with iNOS gene transfer as well as treatment with the NO-donor S-nitroso-N-acetylpenicillamine (SNAP), demonstrating the p53-independent nature of these NO-mediated pathways. The transfer of the iNOS gene activated the p42/44 MAPK, and inhibition of this MAPK pathway with PD98059 partially blocked the antiproliferative effects of NO and completely inhibited the p21 stimulatory effects of NO. For confirmation that iNOS overexpression upregulated p21 in vivo, injured rat carotid arteries were infected with an adenoviral vector carrying the iNOS gene and demonstrated a marked upregulation of p21 expression at three days. However, the ability of NO to inhibit VSMC proliferation does not solely depend on p21 upregulation since the NO-donor SNAP-inhibited VSMC proliferation in p21 -/- VSMCs.
CONCLUSION: Nitric oxide inhibits VSMC proliferation in association with the upregulation of p21; both occur independent of p53 and cGMP while being partially mediated through the p42/44 MAPK signaling cascade. This represents one potential mechanism by which NO inhibits VSMC proliferation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10842159     DOI: 10.1067/mva.2000.105006

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  33 in total

Review 1.  Reactive oxygen and nitrogen species in pulmonary hypertension.

Authors:  Diana M Tabima; Sheila Frizzell; Mark T Gladwin
Journal:  Free Radic Biol Med       Date:  2012-03-06       Impact factor: 7.376

2.  Xanthine Oxidoreductase Function Contributes to Normal Wound Healing.

Authors:  Michael C Madigan; Ryan M McEnaney; Ankur J Shukla; Guiying Hong; Eric E Kelley; Margaret M Tarpey; Mark Gladwin; Brian S Zuckerbraun; Edith Tzeng
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

3.  Insights into the effect of nitric oxide and its metabolites nitrite and nitrate at inhibiting neointimal hyperplasia.

Authors:  Ashley K Vavra; George E Havelka; Janet Martinez; Vanessa R Lee; Bo Fu; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2011-04-30       Impact factor: 4.427

4.  Effect of nitric oxide on neointimal hyperplasia based on sex and hormone status.

Authors:  Melissa E Hogg; Vinit N Varu; Ashley K Vavra; Daniel A Popowich; Monisha N Banerjee; Janet Martinez; Qun Jiang; Joseph E Saavedra; Larry K Keefer; Melina R Kibbe
Journal:  Free Radic Biol Med       Date:  2011-01-21       Impact factor: 7.376

5.  Nitric oxide increases lysine 48-linked ubiquitination following arterial injury.

Authors:  Chris S Oustwani; Nick D Tsihlis; Ashley K Vavra; Qun Jiang; Janet Martinez; Melina R Kibbe
Journal:  J Surg Res       Date:  2011-06-15       Impact factor: 2.192

6.  Polymer-Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications.

Authors:  Michele C Jen; María C Serrano; Robert van Lith; Guillermo A Ameer
Journal:  Adv Funct Mater       Date:  2012-01-25       Impact factor: 18.808

7.  Nitric oxide inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia by increasing the ubiquitination and degradation of UbcH10.

Authors:  Nick D Tsihlis; Chris S Oustwani; Ashley K Vavra; Qun Jiang; Larry K Keefer; Melina R Kibbe
Journal:  Cell Biochem Biophys       Date:  2011-06       Impact factor: 2.194

8.  Role of metabolic environment on nitric oxide mediated inhibition of neointimal hyperplasia in type 1 and type 2 diabetes.

Authors:  Monica P Rodriguez; Zachary M Emond; Zheng Wang; Janet Martinez; Qun Jiang; Melina R Kibbe
Journal:  Nitric Oxide       Date:  2013-12-12       Impact factor: 4.427

9.  Nitric oxide suppression of cellular proliferation depends on cationic amino acid transporter activity in cytokine-stimulated pulmonary endothelial cells.

Authors:  Louis G Chicoine; Louis G Chicione; Michael R Stenger; Hongmei Cui; Andrea Calvert; Rebecca J Evans; B Keith English; Yusen Liu; Leif D Nelin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-01-14       Impact factor: 5.464

10.  Nitric oxide may inhibit neointimal hyperplasia by decreasing isopeptidase T levels and activity in the vasculature.

Authors:  Nick D Tsihlis; Muneera R Kapadia; Ashley K Vavra; Walker D Flannery; Christopher S Oustwani; Qun Jiang; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2013-01-30       Impact factor: 4.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.